Disclosed are thiazolyl-dihydro-quinazolines of general formula (I)
wherein the groups R
1
to R
4
have the meanings given in the claims and specification, the isomers thereof, and processes for preparing these compounds and their use as pharmaceutical compositions.
Novel high affinity quinoline-based kinase ligands
申请人:Deng Yongqi
公开号:US20080045568A1
公开(公告)日:2008-02-21
Quinoline-based inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.
Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus
申请人:Wyeth
公开号:US20030203941A1
公开(公告)日:2003-10-30
This invention provides compounds of formula I, having the structure
1
wherein R
1
, R
2
, R
3
, R
4
, A, and B are as defined in the specification, or a pharmaceutically acceptable salt thereof, that are useful in treating metabolic disorders mediated by insulin resistance or hyperglycemia.
AN EFFICIENT SYNTHESIS OF 3,4-DIHYDRO-1H-2,3-BENZOTHIAZINE 2,2-DIOXIDES USING AMBERLYST 15 AND AMBERLYST XN 1010
作者:Rodolfo D. Bravo、Alicia S. Cánepa
DOI:10.1081/scc-120014987
日期:2002.1
ABSTRACT Resins Amberlyst 15 and Amberlyst XN 1010 are used in the synthesis of 3,4-dihydro-1H-2,3-benzothiazines 2,2-dioxide. Advantages of this new procedure are simple work-up, high yield and selectivity, easy recovery of the catalyst and no waste problems.